264 related articles for article (PubMed ID: 32251410)
21. Research Progress of DCLK1 Inhibitors as Cancer Therapeutics.
Cheng L; Huang S; Chen L; Dong X; Zhang L; Wu C; Ye K; Shao F; Zhu Z; Thorne RF
Curr Med Chem; 2022; 29(13):2261-2273. PubMed ID: 34254905
[TBL] [Abstract][Full Text] [Related]
22. Doublecortin-like kinase 1 is a therapeutic target in squamous cell carcinoma.
Standing D; Arnold L; Dandawate P; Ottemann B; Snyder V; Ponnurangam S; Sayed A; Subramaniam D; Srinivasan P; Choudhury S; New J; Kwatra D; Ramamoorthy P; Roy BC; Shadoin M; Al-Rajabi R; O'Neil M; Gunewardena S; Ashcraft J; Umar S; Weir SJ; Tawfik O; Padhye SB; Biersack B; Anant S; Thomas SM
Mol Carcinog; 2023 Feb; 62(2):145-159. PubMed ID: 36218231
[TBL] [Abstract][Full Text] [Related]
23. Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer.
Tao H; Tanaka T; Okabe K
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1449-1459. PubMed ID: 28382517
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of novel DCLK1 inhibitor containing purine skeleton for the treatment of pancreatic cancer.
Chen Y; Meng L; Wang W; Ye L; Huang L; Wang C; Wang S; Li M; Pei Y; Zhang S; Zou Y; Xu Y
Eur J Med Chem; 2023 Dec; 261():115846. PubMed ID: 37862816
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases.
Ali N; Chandrakesan P; Nguyen CB; Husain S; Gillaspy AF; Huycke M; Berry WL; May R; Qu D; Weygant N; Sureban SM; Bronze MS; Dhanasekaran DN; Houchen CW
Oncotarget; 2015 Aug; 6(24):20327-44. PubMed ID: 25948779
[TBL] [Abstract][Full Text] [Related]
26. miR-613 inhibits the growth and invasiveness of human hepatocellular carcinoma via targeting DCLK1.
Wang W; Zhang H; Wang L; Zhang S; Tang M
Biochem Biophys Res Commun; 2016 May; 473(4):987-992. PubMed ID: 27049311
[TBL] [Abstract][Full Text] [Related]
27. miR-137 Regulates the Tumorigenicity of Colon Cancer Stem Cells through the Inhibition of DCLK1.
Sakaguchi M; Hisamori S; Oshima N; Sato F; Shimono Y; Sakai Y
Mol Cancer Res; 2016 Apr; 14(4):354-62. PubMed ID: 26747706
[TBL] [Abstract][Full Text] [Related]
28. Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis.
Ito H; Tanaka S; Akiyama Y; Shimada S; Adikrisna R; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Yamaoka S; Tanabe M
PLoS One; 2016; 11(1):e0146564. PubMed ID: 26764906
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
Park SY; Kim JY; Choi JH; Kim JH; Lee CJ; Singh P; Sarkar S; Baek JH; Nam JS
Clin Cancer Res; 2019 Feb; 25(4):1415-1429. PubMed ID: 30446587
[TBL] [Abstract][Full Text] [Related]
30. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
[TBL] [Abstract][Full Text] [Related]
31. miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer.
Wang J; Wang S; Zhou J; Qian Q
Biomed Pharmacother; 2018 Jun; 102():147-152. PubMed ID: 29550638
[TBL] [Abstract][Full Text] [Related]
32. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
[TBL] [Abstract][Full Text] [Related]
33. Visualization of stem cell activity in pancreatic cancer expansion by direct lineage tracing with live imaging.
Maruno T; Fukuda A; Goto N; Tsuda M; Ikuta K; Hiramatsu Y; Ogawa S; Nakanishi Y; Yamaga Y; Yoshioka T; Takaori K; Uemoto S; Saur D; Chiba T; Seno H
Elife; 2021 Jan; 10():. PubMed ID: 33393460
[TBL] [Abstract][Full Text] [Related]
34. A pharmacogenomic analysis using L1000CDS
Choi EA; Choi YS; Lee EJ; Singh SR; Kim SC; Chang S
Cancer Lett; 2019 Nov; 465():82-93. PubMed ID: 31404615
[TBL] [Abstract][Full Text] [Related]
35. Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis.
Westphalen CB; Takemoto Y; Tanaka T; Macchini M; Jiang Z; Renz BW; Chen X; Ormanns S; Nagar K; Tailor Y; May R; Cho Y; Asfaha S; Worthley DL; Hayakawa Y; Urbanska AM; Quante M; Reichert M; Broyde J; Subramaniam PS; Remotti H; Su GH; Rustgi AK; Friedman RA; Honig B; Califano A; Houchen CW; Olive KP; Wang TC
Cell Stem Cell; 2016 Apr; 18(4):441-55. PubMed ID: 27058937
[TBL] [Abstract][Full Text] [Related]
36. Application of RNA-sequencing to identify transcriptome modification by DCLK1 in colorectal cancer cells.
Li L; Mei H; Commey ANA
Cancer Gene Ther; 2020 Sep; 27(9):691-701. PubMed ID: 31636360
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic Landscape and Therapeutic Implication of Gene Isoforms of Doublecortin-Like Kinase 1 for Cancer Stem Cells.
Moore LL; Houchen CW
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003596
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a doublecortin-like kinase 1 inhibitor to prevent inflammatory responses in acute lung injury.
Cai B; Xu Y; Luo R; Lu K; Wang Y; Zheng L; Zhang Y; Yin L; Tu L; Luo W; Zheng L; Zhang F; Lv X; Tang Q; Liang G; Chen L
Bioorg Chem; 2024 Apr; 145():107215. PubMed ID: 38394920
[TBL] [Abstract][Full Text] [Related]
39. DCLK1 phosphorylates the microtubule-associated protein MAP7D1 to promote axon elongation in cortical neurons.
Koizumi H; Fujioka H; Togashi K; Thompson J; Yates JR; Gleeson JG; Emoto K
Dev Neurobiol; 2017 Apr; 77(4):493-510. PubMed ID: 27503845
[TBL] [Abstract][Full Text] [Related]
40. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
